Exact Sciences (NASDAQ:EXAS) Posts Earnings Results, Beats Estimates By $0.23 EPS

Exact Sciences (NASDAQ:EXAS) issued its quarterly earnings data on Wednesday. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23, Zacks reports. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. Exact Sciences updated its FY 2025 guidance to EPS.

Exact Sciences Stock Up 1.7 %

Shares of Exact Sciences stock traded up $0.85 during trading on Wednesday, reaching $50.48. The company had a trading volume of 3,328,804 shares, compared to its average volume of 2,212,329. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. Exact Sciences has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The firm’s fifty day moving average is $55.66 and its 200-day moving average is $60.17. The company has a market cap of $9.34 billion, a price-to-earnings ratio of -43.14 and a beta of 1.24.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on EXAS. TD Cowen upped their target price on shares of Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. BTIG Research upped their price objective on shares of Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Robert W. Baird lowered their target price on shares of Exact Sciences from $70.00 to $67.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Evercore ISI reduced their price target on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, William Blair restated an “outperform” rating on shares of Exact Sciences in a report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Exact Sciences has an average rating of “Moderate Buy” and an average price target of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.